On November 2, 2021 Immunetune, a preclinical-stage biotech developing next-generation DNA vaccines against cancer and infectious diseases, reported the upcoming presentations by members of its management team at several industry and scientific conferences during November 2021 (Press release, ImmuneTune, NOV 2, 2021, View Source [SID1234594081]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are looking forward to presenting our platform of synthetic DNA vaccines to an audience of investors, pharma and biotech companies, and scientists and investigators," said Sijme Zeilemaker, CEO of Immunetune. "With our lead program NeoVAC, a personalized neoantigen cancer vaccine, moving towards the clinic in 2022, it is a great opportunity to showcase our unique differentiation and explore collaborations with leaders in this field."
Upcoming conferences:
Drug Discovery Strategic Summit, November 4 – 5, Amsterdam, the Netherlands
CEO Sijme Zeilemaker will be presenting on November 4th, 9:50 – 10:10 AM, on "Next-generation DNA vaccines targeting cancer and infectious diseases".
LSX Investival Showcase, November 8 – 15, Virtual / London, UK
CEO Sijme Zeilemaker will be participating virtually and in person on November 15th in London. Please reach out to [email protected] if you would like to set up a meeting within our scope of investors and pharma/biotech collaborations.
Festival of Biologics / World Immunotherapy Congress, November 9 – 11, Basel, Switzerland
CEO Sijme Zeilemaker will be presenting on November 9th, 5:50 – 6:10 PM, in the Innate & Adaptive Checkpoint Inhibition track on "Neoantigen cancer vaccines based on synthetic linear DNA with a pyroptotic adjuvant synergize with checkpoint inhibitors".
Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting, November 10 – 14, Virtual / Washington, D.C., US
CSO Jeroen van Bergen will be presenting the poster titled "Personalized synthetic polyepitope DNA cancer vaccines encoding a novel pyroptotic adjuvant to generate effective anti-tumor T cell immunity". Abstracts can be accessed on the SITC (Free SITC Whitepaper) website once the conference begins on November 9th; posters will be presented on November 12 and 13.